Board of Directors

The principal duty of the Board is to represent and protect the interests of the Company's shareholders by ensuring that the Company is well-managed in the interests of its shareholders. In doing so, the Board has the legal responsibility for overseeing the affairs of the Company. The Board's oversight function is exercised through the nomination, election and appointment of competent directors.

The Board remains responsible for oversight and has an obligation to keep informed in order to assist Management in formulating, developing and implementing plans and serves as a body to review and provide advice to Management on the operations of the Company. These duties are discharged by the full Board, the Board's Committees and by individual members of the Board, as may be appropriate relative to the circumstance.

Additional information on Board composition, committees, processes, information and functions can be found in the 2010 Annual Report and Accounts in the Financial Information section and also in the Corporate Governance section.

• (A) = Audit
• (N) = Nomination
• (R) = Remuneration

Dr. Peter Fellner, Non-Executive Chairman (A•R•N)

Dr Peter Fellner joined the Company as Chairman with effect from 1 January 2010.

Previously, Dr Fellner served as CEO of Celltech Group Plc from 1990 to 2003 and oversaw its growth from an early-stage R&D company into the UK's largest biotechnology company, a constituent of the FTSE 100 index and also listed on the NYSE. He then served as its Chairman from 2003 until its acquisition in 2004. Dr Fellner joined Celltech from Roche UK, where he served as CEO from 1986 to 1990, having previously been Director of the Roche Research Centre in the UK. Dr Fellner currently serves as Chairman of the medical technology company Consort Medical Plc and of the biotechnology companies Vernalis Plc and Biotie Therapies Corp, and Vice-Chairman of Astex Pharmaceuticals, Inc. He is also a Director of the global biopharmaceutical company UCB SA and is a member of the Novo A/S Advisory Group. He previously served as Chairman of the biotechnology company Acambis Plc and of Premier Research Group Plc, a CRO, until they were each acquired during 2008.

Roy Davis, Chief Executive Officer

Roy Davis joined the Company as Chief Executive Officer with effect from 17 November 2008 with over 25 years of operational line management and strategic consulting experience.

Mr Davis was Chief Executive Officer of Gyrus Group plc, a quoted leading medical device company, from June 2007, before it was acquired by the Olympus Corporation of Japan in February 2008. Before becoming CEO he served as Chief Operating Officer of the company from 2003. Mr Davis joined Gyrus as a Non-executive Director at the time of its flotation in 1997. He was previously CEO of NTERA, a nanotechnology company and before that spent almost ten years with Arthur D Little, the global management consulting company, where he was Vice President and Global Head of its operations management business. Mr Davis has also held senior operational positions for Tricom, Reuters and Molex in the US, Taiwan and Europe. Mr Davis holds a mechanical engineering degree and obtained an MBA from the London Business School.

Louisa Burdett, Chief Financial Officer

Ms Burdett joined Optos from the Financial Times Group, where she had been Chief Financial Officer since 2008.

Prior to that Ms Burdett was Chief Financial Officer of Chep Europe, a division of Brambles Ltd, the Australian listed pallet distribution company. Ms Burdett also spent six years in the healthcare industry at GE Healthcare (formerly Amersham plc). From 2003 to 2007 she was Chief Financial Officer of GE's medical diagnostics business and from 2001 to 2003 she was Finance Director, Global R&D of Amersham's medical diagnostics business. Before joining Amersham, Ms Burdett spent five years with GlaxoSmithKline plc in a number of finance roles, including the integration of GlaxoWellcome and SmithKline Beecham. She has also worked as an M&A Consultant at Charterhouse Bank and spent four years at KPMG in London.

Ms Burdett has a first class degree in Biochemistry from Imperial College, London and is a member of the Institute of Chartered Accountants in England and Wales.

Barry M. Rose, Non-Executive Director (A•N)

Barry Rose joined the Company as a Non-executive Director in December 2005 and serves as the Senior Independent Director to the Board and as Chairman of the Audit Committee.

Mr Rose was Chief Executive of Scottish Provident UK from 1993 to 2001. He is Chairman of Baillie Gifford Shin Nippon plc, Dimensional Imaging Ltd and Circle, a Scottish charity.

Mr Rose is also a Non-executive Director of Aberdeen Smaller High Income Trust plc. Mr Rose has an Honours degree in mathematics from Manchester University.

John Goddard, FCA, Non-Executive Director (A•N)

John Goddard joined the Company as a Non-executive Director in June 2011.

Mr Goddard has had a distinguished career in the global pharmaceuticals industry, the majority of which was with AstraZeneca, where he was ultimately Head of Group Strategic Planning. He has extensive experience of mergers and acquisitions, and had significant involvement in the merger of Astra and Zeneca. Prior to his retirement from AstraZeneca in 2010, Mr Goddard was responsible for building a 100-strong global team focused upon M&A and licensing, which completed 75 transactions in four years, including several acquisitions, in-licensing and out-licensing of compounds, and disposals. Latterly, Mr Goddard became Chairman of the AstraZeneca subsidiary, Aptium Oncology, and of the substantial medical device business, Astratech. Mr Goddard is a member of the Board of Directors of Intas Pharmaceuticals Ltd and Mela Sciences Inc.

Dr. Peter H. Kehoe, Non-Executive Director (R•N)

Dr Peter Kehoe joined the Company as a Non-executive Director in October 2010.

Since 1984, Dr Kehoe has been a principal of Kehoe Eyecare, PC in Galesburg, Illinois, USA. From 1997 to 1998 Dr Kehoe served as President of the Illinois Optometric Association and received their Optometrist of the Year Award in 2001. He served on the Board of Trustees of the American Optometric Association from 1999 to 2010 and as President of the 36,000 member organisation in 2008 to 2009. During his AOA tenure, he co-ordinated the optometric infant and children's vision coalition and was instrumental in the 2005 launch of InfantSEE®, a public health programme offering comprehensive no-cost eye examinations for any child in America in their first year of life. Dr Kehoe serves as a North American representative on the Governing Board of the World Council of Optometry. In 2010, he was named as a consultant to Transitions Optical serving as a Professional Relations Adviser and in 2012 appointed a consultant to Diopsys Inc.

Dr Kehoe holds an OD degree and a Doctor of Science from the Illinois College of Optometry, Chicago. He became a Fellow in the American Academy of Optometry in 1999 and is a Diplomat of the American Board of Optometry.

David Wilson, Non-Executive Director (R•N)

David Wilson joined the Company as a Non-executive Director in June 2011.

Mr Wilson is Chairman and founding partner of WG Partners. He has 26 years' experience in the City, most recently as Deputy Chief Executive of Matrix Corporate Capital. Previously Mr Wilson was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. Mr Wilson has held senior positions at ING Barings as Head of UK Investment Group, Deutsche Bank as Head of Small Companies Corporate Finance and UBS as Head of Small Companies Corporate Broking. Mr Wilson is Senior Board Adviser to Sapia Partners LLP and on the Board of Governors of Harris Academy Bromley.

Rosalyn S. Wilton, Non-Executive Director (R•N)

Rosalyn Wilton joined the Company as a Non-executive Director in August 2007 and serves as Chairman of the Remuneration Committee.

Mrs Wilton stepped down in October 2009 as Chairman of Ipreo Holdings LLC, the US-based financial data and solutions group which was formed following the merger of i-Deal LLC and Hemscott Group Ltd. Before the merger, Mrs Wilton was Chief Executive Officer of Hemscott plc. Mrs Wilton has previously served as Managing Director of Reuters Information Services and Reuters Transactions Products and was a member of the Reuters Executive Committee. Mrs Wilton has held non-executive directorship positions with Scottish Widows and the London International Financial Futures Exchange. Mrs Wilton has previously served as a Senior Adviser to both 3i Investments and Providence Equity Partners. She currently serves as a Non-executive Director of AXA UK, AXA Insurance and AXA Wealth Management and as a Non-Executive Director and Chairman of Secure Health Ltd.

Mrs Wilton holds a BSc (Hons) from the University of London.

Robert Kennedy, Company Secretary

Robert Kennedy joined the Company in August 2011 and holds the position of Group Director of Finance and Company Secretary.

Mr Kennedy joined from the University of Dundee where he had been the Director of Finance since 2007. Prior to this Mr Kennedy held a number of senior finance roles including six years with Gamma Holding NV, the last three as Group Finance Director of the Filtration Division. He also spent three years working at PricewaterhouseCoopers as a Management Consultant.

Mr Kennedy has an honours degree in economics from the University of Sheffield and a MBA from the University of Manchester. He is a member of the Chartered Institute of Management Accountants and the Association of Corporate Treasurers.